Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C

Lignende værker

• The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
  af: Silverman, LR, et al.
  Udgivet: (2008)
• Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes
  af: Seymour, John F., et al.
  Udgivet: (2010)
• Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine
  af: Santini, Valeria, et al.
  Udgivet: (2010)
• Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes
  af: Silverman, Lewis R., et al.
  Udgivet: (2011)
• Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update
  af: Fenaux, P, et al.
  Udgivet: (2008)